Group 1 - The core viewpoint of the article is that China Coal Energy (601898.SH) reported a decline in both coal production and sales in February compared to the previous year [1] Group 2 - In February, the company's coal production was 8.91 million tons, representing a year-on-year decrease of 13.0% [1] - Cumulative coal production for the year reached 19.2 million tons, down 11.6% year-on-year [1] - February coal sales amounted to 16.51 million tons, reflecting a year-on-year decline of 5.5% [1] - Cumulative coal sales for the year were 36.56 million tons, which is a decrease of 7.2% year-on-year [1] - The self-produced coal sales in February were 8.65 million tons, down 10.1% year-on-year [1] - Cumulative self-produced coal sales for the year totaled 19.22 million tons, a decrease of 5.3% year-on-year [1]

格隆汇3月18日丨蒙古能源(00276.HK)公告，蔡文羽由于希望投入更多时间和精力于其现任公司法律及 合规总监职位，故辞任公司非执行董事职务。 ...

Group 1 - The company, Zhaoyan New Drug (06127.HK), announced a board meeting scheduled for March 30, 2026, to consider and approve the annual performance for the year ending December 31, 2025 [1] - The board will also discuss the proposal for a final dividend distribution, if applicable, along with other matters [1]

Group 1 - The core point of the news is that Huya Inc. has announced a new stock repurchase plan, reflecting the company's commitment to enhancing shareholder returns and confidence in future growth [1] - The "2026 Stock Repurchase Plan" allows the company to repurchase up to $50 million worth of shares over a 24-month period ending on March 18, 2028 [1] - The repurchase will be executed using existing funds through various methods such as open market transactions, negotiated transfers, and block trades [1] Group 2 - Huya's latest financial report for Q4 2025 shows significant results from its strategic transformation, with game-related services, advertising, and other revenues increasing by 59.4% year-over-year [2] - Total revenue for Q4 2025 reached 1.74 billion yuan, marking a year-over-year growth [2] - Adjusted operating profit for Q4 2025 has been positive for three consecutive quarters, and the annual adjusted operating profit has also turned positive, indicating improved core operational performance [2]

格隆汇3月18日丨泰格医药(03347.HK)宣布，董事会会议将于2026年3月30日(星期一)举行，藉以(其中包 括)审议及批准公司及其附属公司截至2025年12月31日止年度的全年业绩及其刊发，以及考虑建议派发 末期股息(如适用)。 ...

Group 1 - The company, HeartLink Medical-B (02160.HK), will hold a board meeting on March 30, 2026, to consider and approve the annual performance for the year ending December 31, 2025, along with its release [1] - The board will also consider the proposal for the distribution of a final dividend, if any [1]

格隆汇3月18日丨神冠控股(00829.HK)宣布，董事会会议将于2026年3月30日（星期一）举行，以（其中 包括）审议及批准集团截至2025年12月31日止年度的年度业绩及其刊发，以及审议派付末期股息（如 有）。 ...

Group 1 - The company, Zhaoyan New Drug (06127.HK), announced a board meeting scheduled for March 30, 2026, to consider and approve the annual performance for the year ending December 31, 2025 [1] - The board will also discuss the proposal for a final dividend distribution, if any, along with other matters [1]

格隆汇3月18日丨中国银河(06881.HK)公告，将于2026年3月30日(星期一)举行董事会会议，藉以(其中包 括)考虑及批准公司及其附属公司截至2025年12月31日止年度的业绩及其发布，并考虑派发末期股息(如 有)。 ...

Core Viewpoint - China COSCO Shipping Ports (01199.HK) reported a revenue increase of 11.0% to USD 1.669 billion for the fiscal year ending December 31, 2025, with a profit attributable to equity holders rising by 1.1% to USD 312 million [1] Financial Performance - Revenue increased by 11.0% to USD 1.669 billion [1] - Profit attributable to equity holders rose by 1.1% to USD 312 million [1] - Basic earnings per share were USD 0.0814 [1] Operational Metrics - Total throughput increased by 6.2% to 152,994,965 TEUs (Twenty-foot Equivalent Units) [1] - Equity throughput rose by 3.4% to 46,850,076 TEUs [1] - Total throughput for controlled terminals increased by 1.8% to 33,246,933 TEUs [1] - Total throughput for non-controlled terminals increased by 7.5% to 119,748,032 TEUs [1]